

Virginia Department of Health's HIV Care Services Ryan White Part B Formulary
 Updated: August 16, 2019

GENERIC NAME	AVAILABLE BRAND NAME* Must use generic when available	CLASS OR TYPE OF DRUG** Must be HIV related or for conditions that affect health outcomes related to HIV management
gabapentin	Neurontin	adjuvant therapy
alprazolam	Xanax	anti-anxiety
diazepam	Valium	anti-anxiety
lorazepam	Ativan	anti-anxiety
triazolam	Halcion	anti-anxiety
amoxicillin	Amoxil	anti-bacterial
amoxicillin/clavulanic acid	Augmentin	anti-bacterial
cefuroxime	Ceftin	anti-bacterial
cephalexin	Keflex	anti-bacterial
ciprofloxacin	Cipro	anti-bacterial
dicloxacillin		anti-bacterial
doxycycline	Vibramycin	anti-bacterial
moxifloxacin	Avelox	anti-bacterial
mupirocin	Bactroban	anti-bacterial
nitrofurantoin	Macrobid	anti-bacterial
penicillin		anti-bacterial
warfarin	Coumadin	anti-coagulant
betamethasone/clotrimazole	Lotrisone	anti-infective
clotrimazole	Lotrimin, Mycelex	anti-infective
clotrimazole troches	Mycelex Troches	anti-infective
ketoconazole	Nizoral	anti-infective
metronidazole	Flagyl	anti-infective
nystatin	Mycostatin Susp.	anti-infective
valacyclovir	Valtrex	anti-viral
oseltamivir	Tamiflu	anti-viral
zanamivir	Relenza	anti-viral
amlodipine	Norvasc	cardiac
atenolol	Tenormin	cardiac
clonidine hydrochloride	Catapres,	Cardiac, opioid use disorder treatment
diltiazem	Cardizem	cardiac
doxazosin	Cardura	cardiac
enalapril	Vasotec	cardiac
fosinopril	Monopril	cardiac
irbesartan	Avapro	cardiac

* RWHAP B funds will pay for brand name formulations only if a generic formulation is not available. Brand names listed on the formulary are for reference only. ** Use of medications must be HIV-related, but is not restricted to the indication/use cited on the formulary. Alternatively, the medication must treat a co-morbid condition or disorder that affects HIV management or an individual's health outcomes such as HIV viral load suppression related to HIV management. The information provided is only a resource and does not provide clinical advice or information. ♦The Drug Addiction and Treatment Act of 2000 limits office-based use of buprenorphine-containing products to prescribers who have met the qualifications to receive a waiver. These prescribers will have a special DEA number starting with the letter "X". † By law, methadone can only be dispensed through an opioid treatment program (OTP) certified by the U.S. Substance Abuse and Mental Health Services Administration (SAMHSA).

Virginia Department of Health's HIV Care Services Ryan White Part B
Formulary Updated: August 16, 2019

labetolol	Trandate	cardiac
lisinopril	Zestril	cardiac
losartan	Cozaar	cardiac
metoprolol	Lopressor	cardiac
potassium		cardiac
propranolol	Inderal	cardiac
verapamil	Covera, Calan	cardiac

GENERIC NAME	AVAILABLE BRAND NAME* Must use generic when available	CLASS OR TYPE OF DRUG** Must be HIV related or for conditions that affect health outcomes related to HIV management
fluocinonide	Lidex	dermatologic
imiquimod	Aldara Cream	dermatologic
bacitracin/neomycin/polymyxin B	Neosporin	dermatologic
triamcinolone: Eucerin (compound)		dermatologic
diphenoxylate/atropine	Lomotil, Lonox	diarrhea
loperamide	Imodium	diarrhea
furosemide	Lasix	diuretic
hydrochlorothiazide		diuretic
spironolactone	Aldactone	diuretic
levothyroxine	Synthroid	hormone
prednisone	Deltasone	hormone
testosterone	Androderm, Androderm, Oxandrin	hormone
buprenorphine/naloxone	Suboxone (sublingual film), Zubsolv (sublingual tablet), Bunavail (buccal film)	opioid use disorder treatment
Buprenorphine (monoproduct)	Sublocade (injection), buprenorphine tablets	opioid use disorder treatment♦
lofexidine	Lucemyra	opioid use disorder treatment
methadone	Dolophine, Methadose	opioid use disorder treatment¥
naltrexone	Vivitrol (tablet and injection)	opioid use disorder treatment, alcohol use disorder treatment
acetaminophen/codeine	Tylenol 3	pain
butalbital/acetaminophen/caffeine	Fioricet	pain
celecoxib	Celebrex	pain
fentanyl	Duragesic	pain
hydrocodone	Hycodan, Lortab, Vicodin	pain
hydromorphone	Dilaudid	pain

* RWHAP B funds will pay for brand name formulations only if a generic formulation is not available. Brand names listed on the formulary are for reference only. ** Use of medications must be HIV-related, but is not restricted to the indication/use cited on the formulary. Alternatively, the medication must treat a co-morbid condition or disorder that affects HIV management or an individual's health outcomes such as HIV viral load suppression related to HIV management. The information provided is only a resource and does not provide clinical advice or information. ♦The Drug Addiction and Treatment Act of 2000 limits office-based use of buprenorphine-containing products to prescribers who have met the qualifications to receive a waiver. These prescribers will have a special DEA number starting with the letter "X". ¥ By law, methadone can only be dispensed through an opioid treatment program (OTP) certified by the U.S. Substance Abuse and Mental Health Services Administration (SAMHSA).

Virginia Department of Health's HIV Care Services Ryan White Part B
Formulary Updated: August 16, 2019

methadone	Dolophine	Pain,
morphine sulphate	MS Contin	pain
naproxen sodium	Naprosyn, Alleve	pain
oxycodone	Roxicodone, OxyContin	pain
propoxyphene	Darvon, Darvocet	pain
tramadol	Ultram	pain
albuterol	Ventolin, Accuneb, Duoneb, Proventil	respiratory
beclomethasone	QVAR	respiratory
guaifenesin/codeine		respiratory
salmeterol	Serevent	respiratory
carbamazepine	Tegretol	seizures
GENERIC NAME	AVAILABLE BRAND NAME* Must use generic when available	CLASS OR TYPE OF DRUG** Must be HIV related or for conditions that affect health outcomes related to HIV management
clonazepam	Klonopin	seizures
divalproex sodium	Depakote	seizures
phenytoin	Dilantin	seizures
temazepam	Restoril	sleep
zolpidem	Ambien	sleep
dronabinol	Marinol	wasting
meningococcal conjugate		vaccine

* RWHAP B funds will pay for brand name formulations only if a generic formulation is not available. Brand names listed on the formulary are for reference only. ** Use of medications must be HIV-related, but is not restricted to the indication/use cited on the formulary. Alternatively, the medication must treat a co-morbid condition or disorder that affects HIV management or an individual's health outcomes such as HIV viral load suppression related to HIV management. The information provided is only a resource and does not provide clinical advice or information. ♦The Drug Addiction and Treatment Act of 2000 limits office-based use of buprenorphine-containing products to prescribers who have met the qualifications to receive a waiver. These prescribers will have a special DEA number starting with the letter "X". † By law, methadone can only be dispensed through an opioid treatment program (OTP) certified by the U.S. Substance Abuse and Mental Health Services Administration (SAMHSA).